News and Announcements
Sequoia Capital backed Incomlend completes over USD 400 million in trade receivable transactions
- Published January 03, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Incomlend provides credit-insured, short-term credit opportunities of 5-7% p.a. in USD.
Incomlend is an award-winning global trade finance fintech-platform merging cross-border factoring and supply chain finance solutions to companies worldwide with insured, uncorrelated private credit opportunities for accredited investors and has financed over USD 400 million of receivables since inception in 2016.
In 2019, Incomlend announced a major partnership with CMA CGM Group on SHIPFIN Trade Finance, an Incomlend-developed solution exclusively for CMA CGM to deliver trade finance services, to its clients. In 2020, Incomlend was awarded the Best Fintech Startup at the GTR Leaders in Trade Award. Incomlend also closed a USD 20 million Series A round led by Sequoia Capital India and CMA CGM Group, that will allow the firm to continue advancing their capabilities in digital invoice finance underwriting and processing.
Accredited investors can access the fast growing and booming SME segment across multiple sectors in South East Asia, Europe, and America through Incomlend by participating either directly on the Incomlend platform, where investors can pick and choose their short-term insured private credit opportunity and potentially earn uncorrelated yield of 5-7%, or through a dedicated Luxembourg based Reserved Alternative Investment Fund managed by an independent Alternative Asset Manager that has historically yielded 5-7%.
To get started, simply reach out to us at [email protected]
About Incomlend
Incomlend works as a marketplace, where SME businesses can optimize their working capital by tapping into a pool of accredited Investors comprising of High Net-worth Individuals, Family Offices, Funds and Institutional Investors . Incomlend has financed over 400MM USD of receivable since inception in 2016 and in 2019 alone Incomlend financed 250MM of invoices.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
